ArticleMolecular oncology2016
Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Article in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Drug repurposing in oncology: a systematic review of anticancer effects of Lanatoside C at the molecular level.BMC cancer · 2025Pooled it
- Injectable thermoresponsive hydrogel scaffold for enhanced delivery of next-generation induced neural stem cells for treatment of glioblastoma.Drug delivery and translational research · 2026Article
- Injectable thermo-responsive hydrogel scaffold for enhanced delivery of second-generation induced neural stem cells for treatment of glioblastoma.Research square · 2026Article
- PBI-05204, a supercritical CONeoplasia (New York, N.Y.) · 2024Article
- Viruses in glioblastoma: an update on evidence and clinical trials.BJC reports · 2024Review
- Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024Review
- Gene Therapy for High Grade Glioma: The Clinical Experience.Expert opinion on biological therapy · 2023Review
- Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.Bioengineering & translational medicine · 2022Article
- Article
- Chrysin induces autophagy through the inactivation of the ROS‑mediated Akt/mTOR signaling pathway in endometrial cancer.International journal of molecular medicine · 2021Article
- Adeno-associated virus (AAV)-based gene therapy for glioblastoma.Cancer cell international · 2021Review
- Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy.Journal of visualized experiments : JoVE · 2019Article
- Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies.Nanomaterials (Basel, Switzerland) · 2019Review
- Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery.Journal of neuro-oncology · 2018Article
- Systemic AAV9-IFNβ gene delivery treats highly invasive glioblastoma.Neuro-oncology · 2016Article
- Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.Molecular oncology · 2016Article
- Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.Molecular therapy oncolytics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Glioblastoma (GBM) is the most common malignant brain tumor in adults. We designed an adeno-associated virus (AAV) vector for intracranial delivery of secreted, soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) to GBM tumors in mice and combined it with the TRAIL-sensitizing cardiac glycoside, lanatoside C (lan C). We applied this combined therapy to two different GBM models using human U87 glioma cells and primary patient-derived GBM neural spheres in culture and in orthotopic GBM xenograft models in mice. In U87 cells, conditioned medium from AAV2-sTRAIL expressing cells combined with lan C induced 80% cell death. Similarly, lan C sensitized primary GBM spheres to sTRAIL causing over 90% cell death. In mice bearing intracranial U87 tumors treated with AAVrh.8-sTRAIL, administration of lan C caused a decrease in tumor-associated Fluc signal, while tumor size increased within days of stopping the treatment. Another round of lan C treatment re-sensitized GBM tumor to sTRAIL-induced cell death. AAVrh.8-sTRAIL treatment alone and combined with lanatoside C resulted in a significant decrease in tumor growth and longer survival of mice bearing orthotopic invasive GBM brain tumors. In summary, AAV-sTRAIL combined with lanatoside C induced cell death in U87 glioma cells and patient-derived GBM neural spheres in culture and in vivo leading to an increased in overall mice survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.